Lupatadine fumarate tablets, a new class 3.1 antiallergic drug, was approved for production

According to the information on the website of the State Food and Drug Administration (CFDA), the state of lupatadine fumarate, a new class 3.1 drug under development by Hisilicon, has been changed to "completed the preparation of the certificate - Liaoning Province with the approval" Deng Xiang, the company's board secretary, said, "from the official information, it should be approved After receiving the approval, we will announce the notice, but it will take several months to go public." The original research enterprise of lupatadine fumarate is uriach pharmaceutical company in Spain, which was first listed in Spain on March 15, 2003 At present, only Yangzijiang Pharmaceutical Group is a manufacturing enterprise in China, and hisilico has lost hands with the first domestic imitator Before that, Deng Xiang had repeatedly said to Da wisdom, "the first imitation is not the most important If there are many competitors, though it is the first imitation, there is still no advantage to speak of." According to the public information, the drug is used in the treatment of seasonal or perennial allergic rhinitis As the only anti allergic drug with dual effects of antihistamine and platelet antagonistic activator, it has certain advantages over cetirizine and loratadine, and is expected to become the first-line drug for the treatment of allergic rhinitis Hisico is the leader in the field of parenteral nutrition medicine, characteristic anti infection medicine and hepatobiliary disease medicine In the prospectus, the company has said that it will focus on tracking the development trend of innovation and imitation of generic drugs in the international mainstream market, establish domestic leading new drug variety reserve resources, and lupatadine fumarate will also be included in the company's reserve resources.